A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of active Psoriatic Arthritis (PsA) upon judgment of the treating physician.
Swollen joint count (SJC) \>= 1 out of 66 joints.
Decision on the treatment with Upadacitinib was made prior to any decision to approach the participant to participate in this study.
You may not be if
Cannot be treated with Upadacitinib according to the local Upadacitinib Summary of Product Characteristics (SmPC).
Prior treatment with Upadacitinib.
Currently participating in interventional research or within the last 30 days.
Clareo Health | A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
